Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib by Tanaka, C, Yin, O Q P, Sethuraman, V, Smith, T, Wang, X, Grouss, K, Kantarjian, H, Giles, F, Ottmann, O G, Galitz, L, Schran, H

Get full text

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) by Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H, Ottmann, O G

Get full text

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse... by Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., Dongen, J. J. M. van, Ottmann, O. G.

Get full text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

Get full text

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation by Mian, A A, Rafiei, A, Haberbosch, I, Zeifman, A, Titov, I, Stroylov, V, Metodieva, A, Stroganov, O, Novikov, F, Brill, B, Chilov, G, Hoelzer, D, Ottmann, O G, Ruthardt, M

Get full text

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors by Haense, N, Atmaca, A, Pauligk, C, Steinmetz, K, Marmé, F, Haag, G M, Rieger, M, Ottmann, O G, Ruf, P, Lindhofer, H, Al-Batran, S-E

Get full text

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors by Haense, N, Atmaca, A, Pauligk, C, Steinmetz, K, Marmn, F, Haag, G. M, Rieger, M, Ottmann, O. G, Ruf, P, Lindhofer, H, Al-Batran, S.-E

Get full text

Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitativ... by Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., van Dongen, J. J. M., Ottmann, O. G.

Get full text

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies by Jabbour, Elias, Ottmann, Oliver G, Deininger, Michael, Hochhaus, Andreas

Get full text

The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective by Sessa, C., Cortes, J., Conte, P., Cardoso, F., Choueiri, T., Dummer, R., Lorusso, P., Ottmann, O., Ryll, B., Mok, T., Tempero, M., Comis, S., Oliva, C., Peters, S., Tabernero, J.

Get full text

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations by Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, O G, Rieger, M A

Get full text

High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cel... by Pursche, S., Ottmann, O.G., Ehninger, G., Schleyer, E.

Get full text

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias by Ottmann, Oliver G., Druker, Brian J., Sawyers, Charles L., Goldman, John M., Reiffers, Jose, Silver, Richard T., Tura, Sante, Fischer, Thomas, Deininger, Michael W., Schiffer, Charles A., Baccarani, Michele, Gratwohl, Alois, Hochhaus, Andreas, Hoelzer, Dieter, Fernandes-Reese, Sofia, Gathmann, Insa, Capdeville, Renaud, O'Brien, Stephen G.

Get full text

794: Crizotinib is an allosteric ABL-inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia by Mahajna, J, Khamaisie, H, Ruimi, N, Agbarya, A, Eshel, E, Dally, N, Ottmann, O, Biondi, R, Mian, A.A, Ruthardt, M

Get full text

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell prepa... by Schleyer, E, Pursche, S, Köhne, C.H, Schuler, U, Renner, U, Gschaidmeier, H, Freiberg-Richter, J, Leopold, T, Jenke, A, Bonin, M, Bergemann, T, le Coutre, P, Gruner, M, Bornhäuser, M, Ottmann, O.G, Ehninger, G

Get full text

53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2... by Platzbecker, U, Germing, U, Giagounidis, A, Götze, K, Kiewe, P, Mayer, K, Ottmann, O, Radsak, M, Wolff, T, Haase, D, Hankin, M, Wilson, D, Zhang, X, Laadem, A, Sherman, M, Attie, K

Get full text

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic... by Giebel, Sebastian, Czyz, Anna, Ottmann, Oliver, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Cornelissen, Jan J., Esteve, Jordi, Gorin, Norbert‐Claude, Savani, Bipin, Schmid, Christoph, Mohty, Mohamad, Nagler, Arnon

Get full text

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblas... by Brissot, Eolia, Labopin, Myriam, Beckers, Marielle M, Socié, Gérard, Rambaldi, Alessandro, Volin, Liisa, Finke, Jürgen, Lenhoff, Stig, Kröger, Nicolaus, Ossenkoppele, Gert J, Craddock, Charles F, Yakoub-Agha, Ibrahim, Gürman, Günhan, Russell, Nigel H, Aljurf, Mahmoud, Potter, Michael N, Nagler, Armon, Ottmann, Oliver, Cornelissen, Jan J, Esteve, Jordi, Mohty, Mohamad

Get full text

Genomic organization and regulation of the human interleukin-18 gene by Kalina, U, Ballas, K, Koyama, N, Kauschat, D, Miething, C, Arnemann, J, Martin, H, Hoelzer, D, Ottmann, O G

Get full text

BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity by PUCCETTI, E, GÜLLER, S, ORLETH, A, BRÜGGENOLTE, N, HOELZER, D, OTTMANN, O. G, RUTHARDT, M

Get full text